Optimal [<sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial-Reference-Cited by-同舟云学术

Optimal [¹⁸F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

Published:2024-04-04 Issue:5 Volume:65 Page:708-713
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Gebhart Geraldine,Keyaerts Marleen,Guiot Thomas,Flamen Patrick,Ruiz-Borrego Manuel,Stradella Agostina,Bermejo Begoña,Escriva-de-Romani Santiago,Calvo Martínez Lourdes,Ribelles Nuria,Fernandez-Abad María,Albacar Cinta,Colleoni Marco,Garrigos Laia,Atienza de Frutos Manuel,Dalenc Florence,Prat Aleix,Marmé Frederik,Schmid Peter,Kerrou Khaldoun,Braga Sofia,Gener Petra,Sampayo-Cordero Miguel,Cortés Javier,Pérez-García José Manuel,Llombart-Cussac Antonio

Publisher

Society of Nuclear Medicine

Reference22 articles.

1. Trastuzumab — Mechanism of Action and Use in Clinical Practice

2. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

3. Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis

4. Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

5. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Breast Imaging of HER2-Positive Breast Cancer in the Era of PHERGain Trial: The past, the Present, and the Prospects;Cancer Biotherapy and Radiopharmaceuticals;2024-08-01